ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
艾格里房產
71.23
-0.2600
-0.36%
盤後：
71.23
0.0000
0.00%
19:52 EDT
成交量：
141.24萬
成交額：
1.01億
市值：
88.60億
市盈率：
38.47
高：
71.87
開：
71.87
低：
70.97
收：
71.49
52周最高：
82.08
52周最低：
69.56
股本：
1.24億
流通股本：
1.22億
量比：
1.02
換手率：
1.16%
股息：
3.14
股息率：
4.41%
每股收益(TTM):
1.85
每股收益(LYR):
1.77
淨資產收益率：
3.70%
總資產收益率：
2.40%
市淨率：
1.40
市盈率(LYR):
40.24
資料載入中...
總覽
公司
新聞
公告
Immunome宣佈IM-1617 ADC一期臨床完成首例患者給藥
环球市场播报
·
06/11
緹樂®（注射用維替索妥尤單抗）獲國家藥品監督管理局批准用於治療復發或轉移性宮頸癌成人患者
美通社
·
06/09
雙抗ADC：中國Biotech滾石上山
蓝鲸财经
·
06/08
君實生物(01877)擬以專利設備作價5308萬元入股上海致域生物醫藥 佈局 ADC 與多特異抗體研發
智通财经
·
06/05
晚間重要公告匯總
第一财经
·
06/04
信達生物(01801): IBI343(CLDN18.2 ADC)治療晚期胃癌的新藥上市申請獲國家藥品監督管理局受理
智通财经
·
06/04
中國生物製藥雙創新藥閃耀ASCO：肺癌一線療法PFS顯著延長，全球首個EGFR/c-Met雙抗ADC臨床數據亮眼
财中社
·
06/01
中國生物製藥(01177)：TQB6411「EGFR/C-MET ADC」於2026 ASCO公布I期臨床數據
智通财经
·
06/01
中國生物製藥(01177)：維特柯妥拜單抗「CLDN18.2 ADC」於2026 ASCO公布一線胃癌II期臨床數據
智通财经
·
06/01
科倫博泰研究成果發表於《柳葉刀》主刊
中国财富通
·
05/31
港股異動 | 德琪醫藥-B(06996)升逾5% ATG-022 ADC治療相關胃腺癌關鍵性III期CLINCH-3研究獲臨床批件
智通财经
·
05/29
艾伯維(ABBV.US)CD123 ADC獲批上市
智通财经
·
05/28
港股異動 | 映恩生物-B(09606)升逾5% 與BioNTech合作開發B7-H3 ADC全球Ⅲ期臨床完成首例患者給藥
智通财经
·
05/27
重磅ADC藥物獲批多發性骨髓瘤二線聯合用藥，GSK中國特藥業務部負責人：腫瘤是未來GSK重要增長引擎之一
蓝鲸财经
·
05/19
百億ADC抗癌藥賽道迎新玩家，藥企期待多元化支付提高可及性
澎湃新闻
·
05/15
百利天恒：iza-bren（EGFR×HER3雙抗ADC）獲臨床試驗批准
南方财经网
·
05/12
【灣區早參】第一季末澳門總人口為68.81萬人；陳茂波：粵港澳推動制定「灣區標準」
金吾财讯
·
05/11
科倫博泰生物(06990)：核心產品TROP2 ADC蘆康沙妥珠單抗(sac-TMT) 新增適應症上市申請獲國家藥品監督管理局受理
智通财经网
·
05/08
從AACR看中國創新：ADC與雙抗領跑 授權交易見證含金量
21世纪经济报道
·
04/23
創勝集團醫藥-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER陽性╱HER2陰性乳腺癌PDX模型中顯示出強大的抗腫瘤活性的新數據
智通财经
·
04/23
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/ADC/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ADC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房產","latestPrice":71.23,"timestamp":1789156800000,"preClose":71.49,"halted":0,"volume":1412407,"hourTrading":{"tag":"盘后","latestPrice":71.23,"preClose":71.23,"latestTime":"19:52 EDT","volume":89152,"amount":6350271.741,"timestamp":1789170728005,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0036368722898306185,"floatShares":122178283,"shares":124379300,"eps":1.85165,"marketStatus":"休市中","change":-0.26,"latestTime":"09-11 16:00:00 EDT","open":71.87,"high":71.87,"low":70.97,"amount":100637967.61366999,"amplitude":0.012589,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.85165,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":71.49,"dividendRate":0.044097,"preHourTrading":{"tag":"盘前","latestPrice":71.505,"preClose":71.49,"latestTime":"08:41 EDT","volume":181,"amount":13184.721465,"timestamp":1789130514795,"change":0.015,"changeRate":0.00021,"amplitude":0.038607},"postHourTrading":{"tag":"盘后","latestPrice":71.23,"preClose":71.23,"latestTime":"19:52 EDT","volume":89152,"amount":6350271.741,"timestamp":1789170728005,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0182799229051516,"impliedVol":0.2095,"impliedVolPercentile":0.259},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","floatShares":122178283,"roa":"2.40%","roe":"3.70%","lyrEps":1.77,"volumeRatio":1.0182799229051516,"shares":124379300,"dividePrice":3.141,"high":71.87,"amplitude":0.012589,"preClose":71.49,"low":70.97,"week52Low":69.56,"pbRate":"1.40","psRate":"11.36","week52High":82.08,"institutionHeld":0.85,"latestPrice":71.23,"eps":1.85165,"divideRate":0.044097,"volume":1412407,"delay":0,"ttmEps":1.85165,"open":71.87,"prevYearClose":72.03,"prevWeekClose":72.62,"prevMonthClose":72.25,"prevQuarterClose":75.74,"fiveDayClose":72.73,"twentyDayClose":75.11,"sixtyDayClose":74.73,"dividendPayoutRate":1.7363850728368737,"dividendFrequency":"M","dividendGrowthYears":10,"dividendGrowthRate":0.026999999999999986,"fiveYearAvgDividendRate":0.041531731300358074},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"ADC","amount":0.267,"announcedDate":"2026-09-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-14","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-14"},{"date":"2026-08-31","symbol":"ADC","amount":0.267,"announcedDate":"2026-08-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-31","defaultRemindTime":1788183000000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-15","payableDate":"2026-08-31","currency":"USD","dateTimestamp":1788148800000,"payDate":"2026-09-15"},{"date":"2026-07-31","symbol":"ADC","amount":0.267,"announcedDate":"2026-07-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-31","defaultRemindTime":1785504600000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-14","payableDate":"2026-07-31","currency":"USD","dateTimestamp":1785470400000,"payDate":"2026-08-14"},{"date":"2026-07-30","symbol":"ADC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2026/06","expectedEps":1.11,"defaultRemindTime":1785441600000,"name":null,"time":"盤後","dateTimestamp":1785384000000,"actualEps":null},{"date":"2026-06-30","symbol":"ADC","amount":0.267,"announcedDate":"2026-06-08","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-30","defaultRemindTime":1782826200000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-15","payableDate":"2026-06-30","currency":"USD","dateTimestamp":1782792000000,"payDate":"2026-07-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-28","recordDate":"2016-09-30","paymentDate":"2016-10-14","value":0.48,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2017-01-03","value":0.495,"currency":"USD"},{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-14","value":0.495,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-14","value":0.505,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-13","value":0.505,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2381,"buy":0.381,"hold":0.381,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.381,"analysts":21,"updateTime":1784088000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADC","date":"2026-09-11","current":38.468393,"percent":0.333605,"low":31.539495,"twenty":37.632574,"median":41.2516,"eighty":43.588862,"high":50.705944,"avg":40.750955,"sd":3.756081,"marketCap":8878508241},"quantilePoints":[{"date":"2021-09-17","current":50.119952,"twenty":31.977009,"median":39.430911,"eighty":44.835833,"marketCap":4879377818},{"date":"2021-09-24","current":47.775985,"twenty":31.977009,"median":39.430911,"eighty":44.888065,"marketCap":4651183223},{"date":"2021-10-01","current":47.352376,"twenty":31.977009,"median":39.430911,"eighty":44.941549,"marketCap":4609943235},{"date":"2021-10-08","current":47.670083,"twenty":31.977009,"median":39.430911,"eighty":44.9864,"marketCap":4640873226},{"date":"2021-10-15","current":49.02563,"twenty":31.977009,"median":39.430911,"eighty":45.094688,"marketCap":4772841185},{"date":"2021-10-22","current":49.5269,"twenty":31.977009,"median":39.430911,"eighty":45.190701,"marketCap":4821641836},{"date":"2021-10-29","current":50.169373,"twenty":32.013133,"median":39.571166,"eighty":45.28245,"marketCap":4884189150},{"date":"2021-11-05","current":43.773853,"twenty":32.013133,"median":39.651928,"eighty":45.28245,"marketCap":4934976633},{"date":"2021-11-12","current":43.137928,"twenty":32.029424,"median":39.72736,"eighty":45.28245,"marketCap":4863283742},{"date":"2021-11-19","current":43.008274,"twenty":32.198132,"median":39.802558,"eighty":45.28245,"marketCap":4848666745},{"date":"2021-11-26","current":42.662528,"twenty":32.27459,"median":39.842867,"eighty":45.28245,"marketCap":4809688086},{"date":"2021-12-03","current":42.508177,"twenty":32.348817,"median":39.911012,"eighty":45.28245,"marketCap":4792286899},{"date":"2021-12-10","current":42.891493,"twenty":32.447032,"median":39.953188,"eighty":45.28245,"marketCap":4835501148},{"date":"2021-12-17","current":45.380751,"twenty":32.521786,"median":39.996581,"eighty":45.380751,"marketCap":5116135105},{"date":"2021-12-23","current":46.352906,"twenty":32.588031,"median":40.079057,"eighty":45.406143,"marketCap":5225733953},{"date":"2021-12-31","current":48.175698,"twenty":32.64443,"median":40.10618,"eighty":45.47788,"marketCap":5431231792},{"date":"2022-01-07","current":46.703962,"twenty":32.651599,"median":40.164071,"eighty":45.565296,"marketCap":5265311314},{"date":"2022-01-14","current":46.015352,"twenty":32.70478,"median":40.208708,"eighty":45.667046,"marketCap":5187678797},{"date":"2022-01-21","current":43.267663,"twenty":32.731462,"median":40.224323,"eighty":45.667046,"marketCap":4877909831},{"date":"2022-01-28","current":43.821252,"twenty":32.743358,"median":40.249944,"eighty":45.667046,"marketCap":4940320287},{"date":"2022-02-04","current":42.666817,"twenty":32.769192,"median":40.314701,"eighty":45.667046,"marketCap":4810171655},{"date":"2022-02-11","current":42.565551,"twenty":32.769192,"median":40.347561,"eighty":45.667046,"marketCap":4798755108},{"date":"2022-02-18","current":42.943612,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4841376882},{"date":"2022-02-25","current":37.784604,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4620036905},{"date":"2022-03-04","current":38.267307,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4679058463},{"date":"2022-03-11","current":37.29027,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4559593141},{"date":"2022-03-18","current":37.24956,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4554615419},{"date":"2022-03-25","current":38.110019,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4659826391},{"date":"2022-04-01","current":39.298046,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4805089927},{"date":"2022-04-08","current":39.763938,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4862056020},{"date":"2022-04-14","current":40.742313,"twenty":32.769192,"median":40.404479,"eighty":45.667046,"marketCap":4981684815},{"date":"2022-04-22","current":42.01187,"twenty":32.769192,"median":40.455317,"eighty":45.667046,"marketCap":5136917418},{"date":"2022-04-29","current":39.554287,"twenty":32.79826,"median":40.479695,"eighty":45.667046,"marketCap":4836421278},{"date":"2022-05-06","current":39.499614,"twenty":32.904642,"median":40.479695,"eighty":45.667046,"marketCap":5066773466},{"date":"2022-05-13","current":39.967203,"twenty":32.996397,"median":40.479695,"eighty":45.667046,"marketCap":5126753027},{"date":"2022-05-20","current":39.90291,"twenty":33.05702,"median":40.479695,"eighty":45.667046,"marketCap":5118505838},{"date":"2022-05-27","current":40.353768,"twenty":33.088236,"median":40.495181,"eighty":45.667046,"marketCap":5176339242},{"date":"2022-06-03","current":40.599257,"twenty":33.156377,"median":40.53176,"eighty":45.667046,"marketCap":5207829139},{"date":"2022-06-10","current":41.119461,"twenty":33.227354,"median":40.613635,"eighty":45.667046,"marketCap":5274557730},{"date":"2022-06-17","current":40.213488,"twenty":33.270165,"median":40.613635,"eighty":45.667046,"marketCap":5158345016},{"date":"2022-06-24","current":43.32302,"twenty":33.260026,"median":40.659236,"eighty":45.668114,"marketCap":5557217043},{"date":"2022-07-01","current":42.978166,"twenty":33.330747,"median":40.684242,"eighty":45.668114,"marketCap":5512981235},{"date":"2022-07-08","current":42.872956,"twenty":33.466784,"median":40.715658,"eighty":45.668114,"marketCap":5499485565},{"date":"2022-07-15","current":43.708789,"twenty":33.59929,"median":40.742313,"eighty":45.668114,"marketCap":5606701167},{"date":"2022-07-22","current":44.556311,"twenty":33.59929,"median":40.778643,"eighty":45.668114,"marketCap":5715416287},{"date":"2022-07-29","current":46.520226,"twenty":33.675236,"median":40.820493,"eighty":45.678143,"marketCap":5967335462},{"date":"2022-08-05","current":43.100932,"twenty":33.675236,"median":40.862996,"eighty":45.68777,"marketCap":6116022220},{"date":"2022-08-12","current":44.318758,"twenty":33.675236,"median":40.912721,"eighty":45.68777,"marketCap":6288831702},{"date":"2022-08-19","current":44.509569,"twenty":33.675236,"median":40.969109,"eighty":45.68777,"marketCap":6315907842},{"date":"2022-08-26","current":43.241234,"twenty":33.675236,"median":41.010201,"eighty":45.68777,"marketCap":6135931147},{"date":"2022-09-02","current":41.585665,"twenty":33.675236,"median":41.060268,"eighty":45.68777,"marketCap":5901005814},{"date":"2022-09-09","current":41.956063,"twenty":33.675236,"median":41.092655,"eighty":45.68777,"marketCap":5953565380},{"date":"2022-09-16","current":40.805583,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5790312183},{"date":"2022-09-23","current":39.935707,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5666876838},{"date":"2022-09-30","current":37.927001,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5381841428},{"date":"2022-10-07","current":36.428553,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5169211706},{"date":"2022-10-14","current":35.631626,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5056127734},{"date":"2022-10-21","current":36.636203,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5198677248},{"date":"2022-10-28","current":38.359137,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5443161610},{"date":"2022-11-04","current":41.724424,"twenty":33.675236,"median":41.119461,"eighty":45.68777,"marketCap":6035896875},{"date":"2022-11-11","current":42.347632,"twenty":33.675236,"median":41.160749,"eighty":45.68777,"marketCap":6126050848},{"date":"2022-11-18","current":42.756995,"twenty":33.675236,"median":41.197005,"eighty":45.68777,"marketCap":6185269635},{"date":"2022-11-25","current":43.056379,"twenty":33.675236,"median":41.218321,"eighty":45.68777,"marketCap":6228578896},{"date":"2022-12-02","current":43.196907,"twenty":33.675236,"median":41.257018,"eighty":45.68777,"marketCap":6248907733},{"date":"2022-12-09","current":43.795676,"twenty":33.675236,"median":41.35326,"eighty":45.68777,"marketCap":6335526256},{"date":"2022-12-16","current":43.172467,"twenty":33.675236,"median":41.423201,"eighty":45.68777,"marketCap":6245372283},{"date":"2022-12-23","current":43.685698,"twenty":33.675236,"median":41.463369,"eighty":45.68777,"marketCap":6319616732},{"date":"2022-12-30","current":43.337434,"twenty":33.675236,"median":41.483593,"eighty":45.68777,"marketCap":6269236570},{"date":"2023-01-06","current":43.245786,"twenty":34.167053,"median":41.539601,"eighty":45.68777,"marketCap":6255978633},{"date":"2023-01-13","current":45.714181,"twenty":34.992765,"median":41.587683,"eighty":45.704396,"marketCap":6613059075},{"date":"2023-01-20","current":45.402576,"twenty":35.880519,"median":41.605991,"eighty":45.714503,"marketCap":6567982088},{"date":"2023-01-27","current":45.378137,"twenty":36.169649,"median":41.646285,"eighty":45.714503,"marketCap":6564446638},{"date":"2023-02-03","current":45.255939,"twenty":36.592515,"median":41.674422,"eighty":45.714503,"marketCap":6546769389},{"date":"2023-02-10","current":44.406665,"twenty":36.713651,"median":41.711398,"eighty":45.714503,"marketCap":6423912504},{"date":"2023-02-17","current":44.157808,"twenty":36.89773,"median":41.739833,"eighty":45.714503,"marketCap":6731283715},{"date":"2023-02-24","current":42.410386,"twenty":36.963658,"median":41.754028,"eighty":45.714503,"marketCap":6464912060},{"date":"2023-03-03","current":41.690165,"twenty":37.214665,"median":41.783816,"eighty":45.714503,"marketCap":6355123742},{"date":"2023-03-10","current":39.423241,"twenty":37.286636,"median":41.783816,"eighty":45.714503,"marketCap":6009560514},{"date":"2023-03-17","current":40.355986,"twenty":37.342014,"median":41.783816,"eighty":45.714503,"marketCap":6151745384},{"date":"2023-03-24","current":39.606247,"twenty":37.466803,"median":41.783816,"eighty":45.714503,"marketCap":6037457546},{"date":"2023-03-31","current":40.621801,"twenty":37.536428,"median":41.78137,"eighty":45.714342,"marketCap":6192265465},{"date":"2023-04-06","current":39.692254,"twenty":37.577737,"median":41.783816,"eighty":45.714503,"marketCap":6050568092},{"date":"2023-04-14","current":39.289647,"twenty":37.687654,"median":41.784219,"eighty":45.714663,"marketCap":5989195981},{"date":"2023-04-21","current":39.792905,"twenty":37.872566,"median":41.784621,"eighty":45.714824,"marketCap":6065911119},{"date":"2023-04-28","current":40.118543,"twenty":37.943837,"median":41.797292,"eighty":45.714985,"marketCap":6115550327},{"date":"2023-05-05","current":39.964605,"twenty":38.110019,"median":41.797292,"eighty":45.714985,"marketCap":6092084520},{"date":"2023-05-12","current":39.104119,"twenty":38.249787,"median":41.797292,"eighty":45.714985,"marketCap":6176026400},{"date":"2023-05-19","current":38.898029,"twenty":38.342909,"median":41.797292,"eighty":45.714985,"marketCap":6143476946},{"date":"2023-05-26","current":37.796919,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5969569863},{"date":"2023-06-02","current":37.832249,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5975149770},{"date":"2023-06-09","current":38.668386,"twenty":38.476762,"median":41.797292,"eighty":45.714985,"marketCap":6107207554},{"date":"2023-06-16","current":38.786152,"twenty":38.533217,"median":41.797292,"eighty":45.714985,"marketCap":6125807242},{"date":"2023-06-23","current":38.509402,"twenty":38.553397,"median":41.809962,"eighty":45.718688,"marketCap":6082097976},{"date":"2023-06-30","current":38.55062,"twenty":38.5799,"median":41.81327,"eighty":45.72239,"marketCap":6088607866},{"date":"2023-07-07","current":38.662498,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6106277570},{"date":"2023-07-14","current":38.603615,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6096977726},{"date":"2023-07-21","current":39.357316,"twenty":38.659115,"median":41.81327,"eighty":45.72239,"marketCap":6216015729},{"date":"2023-07-28","current":39.404422,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6223455604},{"date":"2023-08-04","current":38.053978,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6196443469},{"date":"2023-08-11","current":37.511193,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6108060089},{"date":"2023-08-18","current":36.166029,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5889023018},{"date":"2023-08-25","current":36.531819,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5948585730},{"date":"2023-09-01","current":36.472821,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5938978841},{"date":"2023-09-08","current":35.75304,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5821774794},{"date":"2023-09-15","current":35.446248,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5771818971},{"date":"2023-09-22","current":33.711695,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5489376431},{"date":"2023-09-29","current":32.567126,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5303002783},{"date":"2023-10-06","current":32.649724,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5316452427},{"date":"2023-10-13","current":31.806046,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5179073913},{"date":"2023-10-20","current":32.41963,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5278985560},{"date":"2023-10-27","current":33.181375,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5472604212},{"date":"2023-11-03","current":35.377246,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5834769220},{"date":"2023-11-10","current":34.598655,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5706356142},{"date":"2023-11-17","current":35.425908,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5842795038},{"date":"2023-11-24","current":35.170433,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5800659496},{"date":"2023-12-01","current":36.015934,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5940108073},{"date":"2023-12-08","current":36.873602,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6081563104},{"date":"2023-12-15","current":37.7556,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6227031044},{"date":"2023-12-22","current":37.968496,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6262143995},{"date":"2023-12-29","current":38.607184,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":6367482847},{"date":"2024-01-05","current":38.296964,"twenty":38.756995,"median":41.871582,"eighty":45.73451,"marketCap":6316318262},{"date":"2024-01-12","current":38.090151,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":6282208538},{"date":"2024-01-19","current":36.989174,"twenty":38.764196,"median":41.872103,"eighty":45.735522,"marketCap":6100624420},{"date":"2024-01-26","current":36.295741,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":5986256523},{"date":"2024-02-02","current":37.232484,"twenty":38.697827,"median":41.871582,"eighty":45.73451,"marketCap":6140753507},{"date":"2024-02-09","current":35.261674,"twenty":38.661168,"median":41.871582,"eighty":45.73451,"marketCap":5815707904},{"date":"2024-02-16","current":33.847315,"twenty":38.629468,"median":41.871582,"eighty":45.73451,"marketCap":5752655855},{"date":"2024-02-23","current":33.670228,"twenty":38.597685,"median":41.871582,"eighty":45.73451,"marketCap":5722558249},{"date":"2024-03-01","current":32.436519,"twenty":38.556509,"median":41.871061,"eighty":45.733498,"marketCap":5512878257},{"date":"2024-03-08","current":33.758772,"twenty":38.535146,"median":41.871061,"eighty":45.733498,"marketCap":5737607052},{"date":"2024-03-15","current":32.6018,"twenty":38.489062,"median":41.871061,"eighty":45.733498,"marketCap":5540969356},{"date":"2024-03-22","current":33.262927,"twenty":38.456408,"median":41.871061,"eighty":45.733498,"marketCap":5653333754},{"date":"2024-03-28","current":33.457723,"twenty":38.385748,"median":41.784621,"eighty":45.733498,"marketCap":5686441121},{"date":"2024-04-05","current":33.192092,"twenty":38.338315,"median":41.766476,"eighty":45.73451,"marketCap":5641294711},{"date":"2024-04-12","current":33.499043,"twenty":38.271415,"median":41.746116,"eighty":45.73451,"marketCap":5693463896},{"date":"2024-04-19","current":32.99201,"twenty":38.226469,"median":41.73308,"eighty":45.73451,"marketCap":5607289064},{"date":"2024-04-26","current":33.647761,"twenty":38.150217,"median":41.720309,"eighty":45.733498,"marketCap":5827926731},{"date":"2024-05-03","current":33.618779,"twenty":38.090151,"median":41.711398,"eighty":45.733498,"marketCap":5822906984},{"date":"2024-05-10","current":34.482434,"twenty":38.029323,"median":41.69585,"eighty":45.733498,"marketCap":5972495456},{"date":"2024-05-17","current":34.986715,"twenty":37.950247,"median":41.66791,"eighty":45.733498,"marketCap":6059839061},{"date":"2024-05-24","current":34.198413,"twenty":37.871294,"median":41.619337,"eighty":45.733498,"marketCap":5923301932},{"date":"2024-05-31","current":34.928752,"twenty":37.820473,"median":41.602226,"eighty":45.733498,"marketCap":6049799566},{"date":"2024-06-07","current":35.908334,"twenty":37.7418,"median":41.585665,"eighty":45.733498,"marketCap":6219467028},{"date":"2024-06-14","current":35.311311,"twenty":37.642264,"median":41.478607,"eighty":45.73451,"marketCap":6116060232},{"date":"2024-06-21","current":35.485201,"twenty":37.563829,"median":41.447441,"eighty":45.735522,"marketCap":6146178716},{"date":"2024-06-28","current":35.734443,"twenty":37.537078,"median":41.447441,"eighty":45.738558,"marketCap":6189348544},{"date":"2024-07-05","current":35.879352,"twenty":37.482188,"median":41.447441,"eighty":45.738558,"marketCap":6214447281},{"date":"2024-07-12","current":36.957471,"twenty":37.418215,"median":41.439295,"eighty":45.738558,"marketCap":6401181884},{"date":"2024-07-15","current":37.189325,"twenty":37.412399,"median":41.439295,"eighty":45.738558,"marketCap":6441339863},{"date":"2024-08-02","current":37.993919,"twenty":37.339153,"median":41.40142,"eighty":45.707657,"marketCap":7107142493},{"date":"2024-08-09","current":38.417922,"twenty":37.339153,"median":41.351038,"eighty":45.669183,"marketCap":7186456557},{"date":"2024-08-16","current":38.455492,"twenty":37.339153,"median":41.248609,"eighty":45.587895,"marketCap":7193484385},{"date":"2024-08-23","current":38.879496,"twenty":37.339153,"median":41.197005,"eighty":45.51208,"marketCap":7272798449},{"date":"2024-08-30","current":39.104915,"twenty":37.339153,"median":41.152223,"eighty":45.432939,"marketCap":7314965420},{"date":"2024-09-06","current":40.19981,"twenty":37.339153,"median":41.109476,"eighty":45.406991,"marketCap":7519776420},{"date":"2024-09-13","current":40.725789,"twenty":37.339153,"median":41.060268,"eighty":45.379705,"marketCap":7618166018},{"date":"2024-09-20","current":39.786541,"twenty":37.339153,"median":41.020981,"eighty":45.296882,"marketCap":7442470307},{"date":"2024-09-27","current":39.931453,"twenty":37.339153,"median":40.992653,"eighty":45.271719,"marketCap":7469577645},{"date":"2024-10-04","current":40.355457,"twenty":37.339153,"median":40.937316,"eighty":45.211095,"marketCap":7548891709},{"date":"2024-10-11","current":39.3196,"twenty":37.339153,"median":40.894276,"eighty":45.159517,"marketCap":7355124439},{"date":"2024-10-18","current":40.731156,"twenty":37.339153,"median":40.838938,"eighty":45.089028,"marketCap":7619169993},{"date":"2024-10-25","current":42.532506,"twenty":37.339153,"median":40.820493,"eighty":45.046981,"marketCap":8077475775},{"date":"2024-10-31","current":40.816625,"twenty":37.339153,"median":40.816625,"eighty":44.988744,"marketCap":7751607762},{"date":"2024-11-08","current":40.076878,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7611120201},{"date":"2024-11-15","current":41.115788,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7808422584},{"date":"2024-11-22","current":41.948003,"twenty":37.338438,"median":40.773001,"eighty":44.914929,"marketCap":7966471090},{"date":"2024-11-29","current":41.773945,"twenty":37.338438,"median":40.773001,"eighty":44.914324,"marketCap":7933415193},{"date":"2024-12-06","current":40.849261,"twenty":37.338438,"median":40.770318,"eighty":44.892115,"marketCap":7757805742},{"date":"2024-12-13","current":40.055121,"twenty":37.338438,"median":40.736734,"eighty":44.892115,"marketCap":7606988214},{"date":"2024-12-20","current":37.770608,"twenty":37.338438,"median":40.680888,"eighty":44.892115,"marketCap":7173129570},{"date":"2024-12-27","current":38.515795,"twenty":37.338438,"median":40.640959,"eighty":44.892115,"marketCap":7314650128},{"date":"2025-01-03","current":37.933788,"twenty":37.338438,"median":40.614232,"eighty":44.892115,"marketCap":7204119473},{"date":"2025-01-10","current":37.906591,"twenty":37.337724,"median":40.580698,"eighty":44.89414,"marketCap":7198954490},{"date":"2025-01-17","current":39.244663,"twenty":37.333873,"median":40.538993,"eighty":44.89414,"marketCap":7453071695},{"date":"2025-01-24","current":38.87479,"twenty":37.333873,"median":40.501145,"eighty":44.89414,"marketCap":7382827915},{"date":"2025-01-31","current":39.761398,"twenty":37.333873,"median":40.465332,"eighty":44.84311,"marketCap":7551206388},{"date":"2025-02-07","current":39.74508,"twenty":37.333873,"median":40.424995,"eighty":44.718497,"marketCap":7548107398},{"date":"2025-02-14","current":40.634976,"twenty":37.333873,"median":40.403761,"eighty":44.67404,"marketCap":7688015540},{"date":"2025-02-21","current":40.363435,"twenty":37.333873,"median":40.374953,"eighty":44.653159,"marketCap":7636640801},{"date":"2025-02-28","current":41.687197,"twenty":37.333873,"median":40.374953,"eighty":44.559412,"marketCap":7887092651},{"date":"2025-03-07","current":42.394335,"twenty":37.33306,"median":40.37194,"eighty":44.562299,"marketCap":8020881032},{"date":"2025-03-14","current":42.767704,"twenty":37.33306,"median":40.383179,"eighty":44.562299,"marketCap":8091521298},{"date":"2025-03-21","current":43.141073,"twenty":37.417052,"median":40.40791,"eighty":44.562299,"marketCap":8162161563},{"date":"2025-03-28","current":42.993988,"twenty":37.479862,"median":40.452151,"eighty":44.562299,"marketCap":8134333580},{"date":"2025-04-04","current":43.440899,"twenty":37.536428,"median":40.487288,"eighty":44.562299,"marketCap":8218887836},{"date":"2025-04-11","current":41.268572,"twenty":37.537078,"median":40.501145,"eighty":44.559412,"marketCap":7807889929},{"date":"2025-04-17","current":44.145605,"twenty":37.540692,"median":40.519212,"eighty":44.559412,"marketCap":8352216066},{"date":"2025-04-25","current":43.782817,"twenty":37.571542,"median":40.572736,"eighty":44.653759,"marketCap":8377141546},{"date":"2025-05-02","current":45.953462,"twenty":37.571542,"median":40.583839,"eighty":44.677947,"marketCap":8792459672},{"date":"2025-05-09","current":43.031008,"twenty":37.571542,"median":40.598117,"eighty":44.677947,"marketCap":8233294969},{"date":"2025-05-16","current":42.422675,"twenty":37.571542,"median":40.624906,"eighty":44.677947,"marketCap":8116900028},{"date":"2025-05-23","current":42.755537,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8180587826},{"date":"2025-05-30","current":42.698147,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8169607171},{"date":"2025-06-06","current":42.411197,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8114703897},{"date":"2025-06-13","current":42.927706,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8213529790},{"date":"2025-06-20","current":43.220395,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8269531129},{"date":"2025-06-27","current":41.894687,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8015878004},{"date":"2025-07-03","current":41.30357,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7902777259},{"date":"2025-07-11","current":40.735409,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7794068777},{"date":"2025-07-18","current":41.234702,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7889600473},{"date":"2025-07-25","current":42.319373,"twenty":37.604201,"median":40.725789,"eighty":44.606841,"marketCap":8097134849},{"date":"2025-08-01","current":42.372392,"twenty":37.604201,"median":40.742491,"eighty":44.606841,"marketCap":7873129491},{"date":"2025-08-08","current":43.918584,"twenty":37.604201,"median":40.752858,"eighty":44.633348,"marketCap":8160424292},{"date":"2025-08-15","current":42.901923,"twenty":37.604201,"median":40.790693,"eighty":44.633348,"marketCap":7971520467},{"date":"2025-08-22","current":44.019656,"twenty":37.604201,"median":40.820493,"eighty":44.633348,"marketCap":8179204204},{"date":"2025-08-29","current":43.199192,"twenty":37.604201,"median":40.894276,"eighty":44.633348,"marketCap":8026755504},{"date":"2025-09-05","current":42.806797,"twenty":37.595885,"median":40.935905,"eighty":44.639951,"marketCap":7953845256},{"date":"2025-09-12","current":43.841294,"twenty":37.604201,"median":40.969944,"eighty":44.633348,"marketCap":8146063183},{"date":"2025-09-19","current":42.527363,"twenty":37.604201,"median":41.008406,"eighty":44.633348,"marketCap":7901924321},{"date":"2025-09-26","current":41.962551,"twenty":37.639342,"median":41.035693,"eighty":44.633348,"marketCap":7796977752},{"date":"2025-10-03","current":42.027951,"twenty":37.639342,"median":41.102705,"eighty":44.633348,"marketCap":7809129460},{"date":"2025-10-10","current":41.974442,"twenty":37.639342,"median":41.115788,"eighty":44.633348,"marketCap":7799187153},{"date":"2025-10-17","current":44.322871,"twenty":37.639342,"median":41.17126,"eighty":44.633348,"marketCap":8235543942},{"date":"2025-10-24","current":44.544295,"twenty":37.639342,"median":41.220151,"eighty":44.656944,"marketCap":8621592904},{"date":"2025-10-31","current":43.1986,"twenty":37.639342,"median":41.2516,"eighty":44.656944,"marketCap":8361132219},{"date":"2025-11-07","current":42.991114,"twenty":37.639342,"median":41.30357,"eighty":44.656944,"marketCap":8320973082},{"date":"2025-11-14","current":43.690638,"twenty":37.639342,"median":41.35326,"eighty":44.656944,"marketCap":8456366743},{"date":"2025-11-21","current":43.68471,"twenty":37.639342,"median":41.452784,"eighty":44.656944,"marketCap":8455219339},{"date":"2025-11-28","current":44.591721,"twenty":37.639342,"median":41.521652,"eighty":44.656944,"marketCap":8630772135},{"date":"2025-12-05","current":44.093754,"twenty":37.639342,"median":41.583569,"eighty":44.656944,"marketCap":8534390208},{"date":"2025-12-12","current":42.244164,"twenty":37.639342,"median":41.619337,"eighty":44.656944,"marketCap":8176400191},{"date":"2025-12-19","current":42.902191,"twenty":37.639342,"median":41.692355,"eighty":44.656944,"marketCap":8303762024},{"date":"2025-12-26","current":42.919976,"twenty":37.639342,"median":41.746748,"eighty":44.656944,"marketCap":8307204236},{"date":"2026-01-02","current":42.700633,"twenty":37.639342,"median":41.754028,"eighty":44.656944,"marketCap":8264750291},{"date":"2026-01-09","current":41.977396,"twenty":37.639342,"median":41.778924,"eighty":44.654358,"marketCap":8124767015},{"date":"2026-01-16","current":42.688777,"twenty":37.639342,"median":41.778924,"eighty":44.603089,"marketCap":8262455483},{"date":"2026-01-23","current":42.700633,"twenty":37.639342,"median":41.778924,"eighty":44.565186,"marketCap":8264750291},{"date":"2026-01-30","current":42.659136,"twenty":37.639342,"median":41.778924,"eighty":44.544295,"marketCap":8256718464},{"date":"2026-02-06","current":45.131184,"twenty":37.639342,"median":41.778924,"eighty":44.513975,"marketCap":8735185890},{"date":"2026-02-13","current":44.908403,"twenty":37.639342,"median":41.778924,"eighty":44.506847,"marketCap":9176987197},{"date":"2026-02-20","current":45.230936,"twenty":37.639342,"median":41.778924,"eighty":44.513975,"marketCap":9242896611},{"date":"2026-02-27","current":46.784962,"twenty":37.639342,"median":41.778924,"eighty":44.52786,"marketCap":9560460154},{"date":"2026-03-06","current":47.517993,"twenty":37.639342,"median":41.778924,"eighty":44.544295,"marketCap":9710254277},{"date":"2026-03-13","current":46.714591,"twenty":37.639342,"median":41.778924,"eighty":44.544295,"marketCap":9546079918},{"date":"2026-03-20","current":46.13403,"twenty":37.639342,"median":41.778924,"eighty":44.544295,"marketCap":9427442972},{"date":"2026-03-27","current":43.629997,"twenty":37.639342,"median":41.778924,"eighty":44.513975,"marketCap":8915746245},{"date":"2026-04-02","current":44.474448,"twenty":37.639342,"median":41.778924,"eighty":44.463484,"marketCap":9088309076},{"date":"2026-04-10","current":45.752298,"twenty":37.639342,"median":41.778924,"eighty":44.447073,"marketCap":9349436265},{"date":"2026-04-17","current":46.315619,"twenty":37.639342,"median":41.778924,"eighty":44.447073,"marketCap":9464550524},{"date":"2026-04-24","current":42.221567,"twenty":37.639342,"median":41.778924,"eighty":44.388105,"marketCap":9263580602},{"date":"2026-05-01","current":42.145034,"twenty":37.639342,"median":41.773945,"eighty":44.310918,"marketCap":9246788997},{"date":"2026-05-08","current":41.718719,"twenty":37.639342,"median":41.749425,"eighty":44.205061,"marketCap":9153253847},{"date":"2026-05-15","current":41.144834,"twenty":37.639342,"median":41.735116,"eighty":44.170042,"marketCap":9027341145},{"date":"2026-05-22","current":41.363457,"twenty":37.639342,"median":41.708673,"eighty":44.159332,"marketCap":9075307889},{"date":"2026-05-29","current":40.745847,"twenty":37.635958,"median":41.645687,"eighty":44.142784,"marketCap":8939801838},{"date":"2026-06-05","current":39.477834,"twenty":37.639342,"median":41.613421,"eighty":44.076208,"marketCap":8661594725},{"date":"2026-06-12","current":40.871555,"twenty":37.639342,"median":41.561825,"eighty":44.020119,"marketCap":8967382716},{"date":"2026-06-18","current":40.341395,"twenty":37.639342,"median":41.522683,"eighty":43.960147,"marketCap":8851063362},{"date":"2026-06-26","current":41.527424,"twenty":37.635958,"median":41.458055,"eighty":43.866662,"marketCap":9111282946},{"date":"2026-07-02","current":41.691391,"twenty":37.635958,"median":41.455214,"eighty":43.838916,"marketCap":9147258004},{"date":"2026-07-10","current":42.549486,"twenty":37.635958,"median":41.455214,"eighty":43.812381,"marketCap":9335527473},{"date":"2026-07-17","current":44.134502,"twenty":37.635958,"median":41.455214,"eighty":43.800235,"marketCap":9683286364},{"date":"2026-07-24","current":43.620739,"twenty":37.635958,"median":41.455214,"eighty":43.790532,"marketCap":9570564516},{"date":"2026-07-31","current":43.306779,"twenty":37.632574,"median":41.452784,"eighty":43.772108,"marketCap":9737919027},{"date":"2026-08-07","current":42.169016,"twenty":37.632574,"median":41.452784,"eighty":43.730794,"marketCap":9482082868},{"date":"2026-08-14","current":41.48415,"twenty":37.632574,"median":41.412647,"eighty":43.686617,"marketCap":9328084404},{"date":"2026-08-21","current":41.119624,"twenty":37.632574,"median":41.35326,"eighty":43.679447,"marketCap":9246117479},{"date":"2026-08-28","current":40.429234,"twenty":37.632574,"median":41.30357,"eighty":43.643751,"marketCap":9090877092},{"date":"2026-09-04","current":40.169647,"twenty":37.632574,"median":41.279794,"eighty":43.619299,"marketCap":9032506706},{"date":"2026-09-11","current":39.48478,"twenty":37.632574,"median":41.2516,"eighty":43.588862,"marketCap":8878508241}],"updateTime":1789345329666},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642280708","title":"Immunome宣佈IM-1617 ADC一期臨床完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280708","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642280708?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 22:26","pubTimestamp":1781187960,"startTime":"0","endTime":"0","summary":"生物技术公司Immunome周三宣布，其潜在首创新药抗体偶联药物IM-1617的一期临床试验已完成首例患者给药。该药物针对一种未公开的实体瘤靶点，用于治疗晚期实体瘤患者。 IM-1617是一款靶向实体瘤的抗体偶联药物，其靶向的是一种促进肿瘤细胞存活并介导免疫细胞排斥的受体酪氨酸激酶。该药物搭载了Immunome专有的拓扑异构酶I抑制剂HC74作为有效载荷。公司计划分别于2026年中和2026年末提交另外两款抗体偶联药物IM-1340和IM-1335的新药临床试验申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-inicaenm0622024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ADC","BK4231","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642523384","title":"緹樂®（注射用維替索妥尤單抗）獲國家藥品監督管理局批准用於治療復發或轉移性宮頸癌成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2642523384","media":"美通社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642523384?lang=zh_tw&edition=fundamental","pubTime":"2026-06-09 13:16","pubTimestamp":1780982160,"startTime":"0","endTime":"0","summary":"在接受维替索妥尤单抗治疗的中国亚组中，未发现新的安全信号。对于在系统治疗期间或治疗后疾病进展的复发或转移性宫颈癌患者，目前的治疗选择有限。维替索妥尤单抗有望为之前接受过治疗的晚期宫颈癌患者提供一种新的治疗选择。维替索妥尤单抗于2024年4月获得美国食品药品监督管理局完全批准。该药物在美国的首次获批可追溯至2021年9月，通过加速批准通道上市，用于治疗在化疗期间或化疗后疾病进展的复发或转移性宫颈癌成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4979181_ZH79181_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4979181_ZH79181_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1066051225.USD","LU2417539215.USD","LU1244550577.SGD","BK4527","IE00BFXG1179.USD","LU0731783394.SGD","SG9999015952.SGD","LU0942090050.USD","LU2237443549.SGD","LU1162221912.USD","09688","LU0098860793.USD","IE00B3PB1722.GBP","LU1221951046.USD","BK4161","ZLAB","L","SG9999015945.SGD","BK1574","ADC","LU1674673428.USD","BK4588","LU1894683264.USD","IE00BZ1G4Q59.USD","LU2237443622.USD","LU1674673691.USD","LU0320765646.SGD","LU1880398471.USD","LU2462157665.USD","BK4515","CSCS","HK0000819398.USD","LU1506573853.SGD","BK4525","IE00BSNM7G36.USD","CSCL","LU1244550494.USD","LU2236285917.USD","IE000M9KFDE8.USD","LU1244550221.USD","LU2102340556.USD","LU1430594728.SGD","LU0868494617.USD","LU2487616109.SGD","LU0053671581.USD","SG9999001440.SGD","LU1066051498.USD","CSCO","ITT","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641310850","title":"雙抗ADC：中國Biotech滾石上山","url":"https://stock-news.laohu8.com/highlight/detail?id=2641310850","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641310850?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 11:21","pubTimestamp":1780888916,"startTime":"0","endTime":"0","summary":"双抗ADC与双载荷ADC合计超100项。大会评选出的100个“重磅ADC”中，中国药企独占72席。在单抗ADC上，中国企业一直在追赶。在双抗ADC上，双方站在了同一条起跑线附近。TQB6411是全球首个公布人体临床数据的EGFR/c-Met双抗ADC。单抗ADC时代的中国药企，大多是在已验证的靶点上做工程化改良。双抗ADC的靶点组合需要从头设计，亲和力差异需要自主设定，这让中国企业第一次有机会在“原创靶点组合”这个维度上站到全球前排。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779680903204339558","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["XBI","BK4581","BK4231","ADC","BK4585","BK4588","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641460591","title":"君實生物(01877)擬以專利設備作價5308萬元入股上海致域生物醫藥 佈局 ADC 與多特異抗體研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2641460591","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641460591?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 22:52","pubTimestamp":1780671175,"startTime":"0","endTime":"0","summary":"作为前述者的代价，代价金额约为人民币5308万元，合资公司将向该公司发行新增注册资本人民币25万元。此外，合资公司拟与姚盛博士及天使轮投资人已订立增资协议，据此，合资公司有条件同意以总代价1500万美元认购合资公司新增注册资本合共人民币 46.875万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","399441","BK4080","BK1583","BK1515","161726","BK4231","XBI","BK4581","BK1161","BK4585","BK4588","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157815","title":"晚間重要公告匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157815","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157815?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 19:53","pubTimestamp":1780574029,"startTime":"0","endTime":"0","summary":"晚间重要公告汇总","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606043760585142.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760585142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4231","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640153816","title":"信達生物(01801): IBI343(CLDN18.2 ADC)治療晚期胃癌的新藥上市申請獲國家藥品監督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640153816","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640153816?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 16:34","pubTimestamp":1780562045,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，IBI343用于晚期胃癌人群的国际III期临床研究按预设方案完成第一次期中分析，达到主要研究终点，IBI343在晚期胃癌治疗中展现出了卓越的疗效和良好的安全性和耐受性。基于这一积极的临床结果，公司已向中国国家药品监督管理局递交IBI343的新药上市申请。IBI343是全球首个获监管审评受理的CLDN18.2靶向ADC药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","LU2242644610.SGD","BK4231","LU2328871848.SGD","BK1589","LU2097828474.EUR","LU0502904849.HKD","BK1161","IPOS","LU0455707207.USD","LU1969619763.USD","LU2097828805.USD","LU2488822045.USD","LU2097828631.EUR","LU2097828557.USD","LU2097828714.EUR","BK1583","ADC","HK0000165453.HKD","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640140982","title":"中國生物製藥雙創新藥閃耀ASCO：肺癌一線療法PFS顯著延長，全球首個EGFR/c-Met雙抗ADC臨床數據亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2640140982","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640140982?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 09:47","pubTimestamp":1780278420,"startTime":"0","endTime":"0","summary":"6月1日，中国生物制药（01177）发布公告，旗下附属公司正大天晴药业集团股份有限公司两项重磅创新药临床研究数据，于2026年美国临床肿瘤学会（ASCO）年会正式公布，涵盖肺癌一线治疗与全球首个EGFR/c-Met双抗ADC两大领域，疗效与安全性数据双双亮眼，彰显公司在肿瘤创新药领域的硬核实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755509132.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755509132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1521","BK1574","BK4211","159992","IE00BZ08YS42.EUR","PFS","BK4195","BK1515","BK1589","BK1191","IE00BZ08YT58.USD","BK4231","06978","01177","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1161","ADC","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640398600","title":"中國生物製藥(01177)：TQB6411「EGFR/C-MET ADC」於2026 ASCO公布I期臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2640398600","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640398600?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 06:53","pubTimestamp":1780267985,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB6411“EGFR/ c-Met ADC”于2026年美国临床肿瘤学会 大会上公布在晚期实体瘤患者中的首次人体I期临床研究数据。研究表明，TQB6411在有效剂量下呈现良好的安全性特征，尤其是血液学毒性较低。作为全球首批公布临床数据的EGFR/c-Met ADC，TQB6411凭借成熟的靶点组合及偏向c-Met端的亲和力设计，在降低研发风险的同时构建了差异化竞争优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","BK1589","LU1989772840.SGD","ADC","LU1989771016.USD","BK4080","BK4585","LU1496350502.SGD","BK1521","IE00BZ08YR35.GBP","MET","BK4231","BK4162","BK1515","BK4588","LU1989772923.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","LU1291159041.SGD","01177","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640798605","title":"中國生物製藥(01177)：維特柯妥拜單抗「CLDN18.2 ADC」於2026 ASCO公布一線胃癌II期臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2640798605","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640798605?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 06:47","pubTimestamp":1780267642,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团全资附属公司礼新医药科技(上海)有限公司自主研发的创新药维特柯妥拜单抗“CLDN18.2 ADC”于2026年美国临床肿瘤学会 大会上公布一线治疗胃或胃食管交界部腺癌的II期临床研究数据。结果显示，LM-302联合PD-1单抗 在CLDN18.2阳性晚期胃或胃食管结合部腺癌一线治疗中展现出令人鼓舞的抗肿瘤活性和可管理的安全性。治疗期间不良事件导致剂量降低的比例分别为17.9%和43.8%，导致治疗终止的比例分别为 23.1%和31.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","BK4080","IE00BZ08YR35.GBP","BK4231","IE00BZ08YT58.USD","BK1589","BK1521","ADC","HK0000165453.HKD","IE00BZ08YS42.EUR","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988823","title":"科倫博泰研究成果發表於《柳葉刀》主刊","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988823","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639988823?lang=zh_tw&edition=fundamental","pubTime":"2026-05-31 19:07","pubTimestamp":1780225620,"startTime":"0","endTime":"0","summary":"5月31日，四川科伦博泰生物医药股份有限公司（6990.HK，以下简称“科伦博泰”）宣布，其自主研发的抗体偶联药物芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性非小细胞肺癌（NSCLC）的III期临床研究（OptiTROP-Lung05）成果，正式发表于国际医学期刊《柳叶刀》主刊，研究同时入选2026年美国临床肿瘤学会（ASCO）年会口头报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605313755196654.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605313755196654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PFS","BK4080","BK4203","HR","ADC","BK4195","BK4225","BK4211","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639648279","title":"港股異動 | 德琪醫藥-B(06996)升逾5% ATG-022 ADC治療相關胃腺癌關鍵性III期CLINCH-3研究獲臨床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2639648279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639648279?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 09:53","pubTimestamp":1780019635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B涨超5%，截至发稿，涨5.33%，报4.35港元，成交额327.19万港元。消息面上，德琪医药-B发布公告，经中国国家药品监督管理局(药监局)药品审评中心审评，本公司已获药审中心核准同意开展关于ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部腺癌的关键性III期CLINCH-3研究。本集团无法保证ATG-022最终将成功开发及上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","III","BK1583","BK4134","ADC","BK4585","BK4231","BK4080","BK1574","BK4588","06996","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638687536","title":"艾伯維(ABBV.US)CD123 ADC獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2638687536","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638687536?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 15:36","pubTimestamp":1779953784,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维宣布美国FDA已经批准其ADC疗法Pivekimab sunirine上市，用于治疗母细胞性浆细胞样树突细胞肿瘤。资料显示，这是全球首个获批上市的CD123 ADC，也是艾伯维首个获批的血液瘤ADC。Pivekimab sunirine是一款靶向CD123的ADC，拟开发用于治疗血液系统恶性肿瘤。CD123靶点在BPDCN肿瘤细胞中呈高度特异性高表达，是该病理想的治疗靶点。美国FDA已于2020年10月授予该药物BPDCN适应症突破性疗法认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0795875169.SGD","LU1732799900.SGD","LU1244550494.USD","LU0472753341.HKD","LU0114720955.EUR","LU0211327993.USD","LU1989771016.USD","LU1267930490.SGD","BK4080","ADC","BK4559","IE00BVYPNV92.GBP","LU2357627491.SGD","LU0029864427.USD","LU0965509101.SGD","SG9999003800.SGD","BK4533","LU1023059063.AUD","LU0289961442.SGD","LU0965509283.SGD","IE00BLSP4239.USD","LU0820561909.HKD","IE00BBT3K403.USD","LU2237443895.HKD","LU2237443465.HKD","LU2089984988.USD","LU0661504455.SGD","LU1267930573.SGD","LU0965509010.AUD","IE000BZT7R73.USD","LU0289739343.SGD","IE0002270589.USD","LU0158827948.USD","BK4581","LU0198837287.USD","IE00B42XCP33.USD","LU1061106388.HKD","BK4566","IPOS","LU1934455277.USD","SG9999011175.SGD","LU1718418525.SGD","SG9999015986.USD","LU1839511570.USD","IE0000B7K699.USD","ABBV","LU2089284900.SGD","SG9999015978.USD","LU1037948897.HKD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638457426","title":"港股異動 | 映恩生物-B(09606)升逾5% 與BioNTech合作開發B7-H3 ADC全球Ⅲ期臨床完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2638457426","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638457426?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 14:56","pubTimestamp":1779864979,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超5%，截至发稿，涨3.14%，报222.6港元，成交额1.52亿港元。消息面上，近日，据映恩生物-B官微消息，公司宣布，与BioNTech SE合作开发的靶向B7-H3的抗体偶联药物DB-1311/BNT324用于治疗未接受过紫杉烷类化疗的转移性去势抵抗性前列腺癌患者的全球Ⅲ期关键性注册临床研究已顺利完成全球首例患者入组给药。2026年5月12日，映恩生物行使独家选择权，参与分摊DB-1311/BNT324在美国地区的研发成本，并共享该药物商业化运营产生的盈亏收益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","HK0000252152.HKD","BK4231","VXUS","BK1161","BK4585","LU2543165471.USD","ADC","HK0000252160.HKD","HK0000500386.USD","BK4080","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636356678","title":"重磅ADC藥物獲批多發性骨髓瘤二線聯合用藥，GSK中國特藥業務部負責人：腫瘤是未來GSK重要增長引擎之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2636356678","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636356678?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 15:41","pubTimestamp":1779176518,"startTime":"0","endTime":"0","summary":"值得注意的是，倍乐锐是GSK肿瘤领域的重磅药物。据GSK全球一季度财报，该药物在今年一季度收入达2300万英镑，在该款药物的加持下，肿瘤业务也已经是GSK当前业绩增长最快的板块。今年第一季度，GSK肿瘤业务销售额同比增长28%，达到5.12亿英镑，业务增速在所有业务中位居第一。GSK副总裁、中国特药业务部负责人张宁向蓝鲸新闻表示，GSK未来会考虑布局更多的ADC药物、小分子药物等形成合力，包括肿瘤在内的特药业务是未来GSK很重要的增长引擎之一。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779176429659930072","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","BK4588","BK4532","GSK","LU1829250122.USD","GSKH","BK4231","BK4007","BK4080","ADC","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635085638","title":"百億ADC抗癌藥賽道迎新玩家，藥企期待多元化支付提高可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=2635085638","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635085638?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 18:17","pubTimestamp":1778840220,"startTime":"0","endTime":"0","summary":"国内ADC（抗体偶联）领域又迎来重磅选手！近日，葛兰素史克（GSK）宣布，其注射用玛贝兰妥单抗（商品名：倍乐锐）与硼替佐米和地塞米松（BVd）联合用于治疗既往接受过至少一线治疗的多发性骨髓瘤成年患者。该药是目前唯一一个获批用于治疗多发性骨髓瘤的抗B细胞成熟抗原（BCMA）ADC药物，可在多种治疗场景中以30分钟的门诊输注方式满足患者多样化的治疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153739072253.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739072253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","ADC","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634629466","title":"百利天恒：iza-bren（EGFR×HER3雙抗ADC）獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2634629466","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634629466?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 17:18","pubTimestamp":1778577480,"startTime":"0","endTime":"0","summary":"南财智讯5月12日电，百利天恒公告，iza-bren（EGFR×HER3双抗ADC）收到国家药品监督管理局《药物临床试验批准通知书》（通知书编号：2026LP01442），同意该药开展联合小分子靶向药物用于治疗驱动基因阳性的局部晚期或转移性非小细胞肺癌的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734555430.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734555430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4231","ADC","02615","688506","91194","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634842770","title":"【灣區早參】第一季末澳門總人口為68.81萬人；陳茂波：粵港澳推動制定「灣區標準」","url":"https://stock-news.laohu8.com/highlight/detail?id=2634842770","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634842770?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 08:57","pubTimestamp":1778461039,"startTime":"0","endTime":"0","summary":"第一季新生婴儿有690名；死亡人数则有673人。随着粤港澳三地推动制定“湾区标准”，香港将成为新兴产业落地大湾区的“国际接口”，以及国家标准与国际标准相互参照的交流与转换平台。公司回购的全部262.85万股H股已于2026年5月8日注销。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YTI1MmE4Njc2MTkyMDEyMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YTI1MmE4Njc2MTkyMDEyMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980975","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861219969.SGD","LU0648948544.HKD","LU1282649141.HKD","LU1282651048.USD","LU1282649067.USD","LU2226123490.SGD","BK1229","IE00BZ08YT58.USD","LU1282651121.HKD","BK1601","00175","LU0384037296.USD","LU0054450605.USD","LU2348773727.SGD","LU0449509016.USD","BK1521","BK1534","LU1282649810.SGD","LU1861214812.USD","LU0264606111.USD","BK1154","LU0572939691.SGD","LU1316543674.SGD","BK1589","HK0000500386.USD","LU0254981946.USD","LU0293314216.USD","BK1539","LU0488056044.USD","00916","LU0572940350.SGD","LU0823040885.USD","SG9999002828.SGD","02276","LU0315179316.USD","03692","EVS.SI","HK0000252152.HKD","LU0214875030.USD","ADC","GELYY","01972","80175","LU0607220059.USD","BK4080","BK1119","BK1191","LU2360107325.USD","IE00BZ08YS42.EUR","LU1211504680.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432300","title":"科倫博泰生物(06990)：核心產品TROP2 ADC蘆康沙妥珠單抗(sac-TMT) 新增適應症上市申請獲國家藥品監督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432300","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432300?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 18:16","pubTimestamp":1778235396,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物 发布公告，近日，本公司靶向人滋养细胞表面抗原2 的抗体偶联药物芦康沙妥珠单抗 (佳泰莱)的一项新增适应症上市申请(该申请)已获中国国家药品监督管理局药品审评中心受理。本次受理是基于OptiTROP-Lung05注册3 期研究的积极结果，该申请是芦康沙妥珠单抗获NMPA受理的第五项适应症上市申请。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ADC","IPOS","06990","BK4231","LU0196878994.USD","BK1161","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629001368","title":"從AACR看中國創新：ADC與雙抗領跑 授權交易見證含金量","url":"https://stock-news.laohu8.com/highlight/detail?id=2629001368","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629001368?lang=zh_tw&edition=fundamental","pubTime":"2026-04-23 13:00","pubTimestamp":1776920400,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛1907年的华盛顿，11位医生与科学家随手组建的“小圈子”，谁也没想到会演变成今天全球癌症研究领域最负盛名的盛会——美国癌症研究协会（AACR）。一百多年后的今天，AACR年会早已不只是一场学术会议，更是全球肿瘤研发的“晴雨表”和“风向标”。对中国生物医药产业而言，AACR也成为观察创新活力与国际化进程的最佳窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604233715799065.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233715799065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629079406","title":"創勝集團醫藥-B(06628)公布其新型LIV1 ADC TST013在前列腺癌及 ER陽性╱HER2陰性乳腺癌PDX模型中顯示出強大的抗腫瘤活性的新數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2629079406","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629079406?lang=zh_tw&edition=fundamental","pubTime":"2026-04-23 07:00","pubTimestamp":1776898849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B 公布，于2026年AACR年会上发表强调其自主研发的LIV1抗体偶联药物的临床前数据。对于LIV1表达的前列腺癌PDX模型，ADC-2在给药两剂后显示出有限的肿瘤生长抑制。总体而言，该等数据证明创胜医药的LIV1 ADC-2及ADC-3项目在ER阳性╱Her2 阴性乳腺癌以及前列腺癌的PDX模型中作为单药疗法显示出强大的抗肿瘤活性。该等结果支持进一步研究创胜医药的LIV1 ADC在LIV1阳性实体瘤中的应用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06628","159938","BK4080","BK4231","BK1515","PDX","BK1161","BK1574","09939","ADC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":107,"code":"91000000","status":"200"}]}}